www.scottishmedicines.org.uk



Healthcare Improvement Scotland



Statement of advice SMC2613

Dermatophagoides pteronyssinus and Dermatophagoides farinae oral lyophilisate (Acarizax[®])

Alk-Abello Ltd



ADVICE: in the absence of a submission from the holder of the marketing authorisation

Dermatophagoides pteronyssinus and Dermatophagoides farina (Acarizax®) is not recommended for use within NHSScotland.

Indication under review:

- Adult patients (18-65 years) diagnosed by clinical history and a positive test of house dust mite sensitisation (skin prick test and/or specific IgE) with at least one of the following conditions:
 - persistent moderate to severe house dust mite allergic rhinitis despite use of symptomrelieving medication
 - house dust mite allergic asthma not well controlled by inhaled corticosteroids and associated with mild to severe house dust mite allergic rhinitis. Patients' asthma status should be carefully evaluated before the initiation of treatment
- Adolescents (12-17 years) diagnosed by clinical history and a positive test of house dust mite sensitisation (skin prick test and/or specific IgE) with persistent moderate to severe house dust mite allergic rhinitis despite use of symptom-relieving medication.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after careful consideration and evaluation of the available evidence. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Vice Chair Scottish Medicines Consortium